navarixin   

GtoPdb Ligand ID: 8497

Synonyms: MK-7123 | MK7123 | SCH-527123 | SCH527123
Compound class: Synthetic organic
Comment: Navarixin (SCH-527123, MK-7123) is a potent and orally bioavailable CXCR2/CXCR1 receptor antagonist [2].
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 111.88
Molecular weight 397.16
XLogP 3.39
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Canonical SMILES CCC(c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C
Isomeric SMILES CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C
InChI InChI=1S/C21H23N3O5/c1-5-13(15-10-9-11(2)29-15)22-16-17(20(27)19(16)26)23-14-8-6-7-12(18(14)25)21(28)24(3)4/h6-10,13,22-23,25H,5H2,1-4H3/t13-/m1/s1
InChI Key RXIUEIPPLAFSDF-CYBMUJFWSA-N
No information available.
Summary of Clinical Use
Navarixin (SCH-527123) has been evaluated in a number of Phase 2 clinical trials for immune conditions such as allergen-induced asthma, chronic obstructive pulmonary disease (COPD) and psoriasis. Development for these indications appears to have been discontinued. As of January 2019 the only active trial involving navarixin is NCT03473925, a Phase 2 study looking for efficacy of navarixin plus pembrolizumab in a selected range of advanced/metastatic solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03473925 Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) Phase 2 Interventional Merck Sharp & Dohme Corp.